

Prescribing and processing oncology and haematology prescriptions for clinical trials

**IT IS THE RESPONSIBILITY OF ALL USERS OF THIS SOP TO ENSURE THAT
THE CORRECT VERSION IS BEING USED**

All staff should regularly check the R&D Unit's website and/or Q-Pulse for information relating to the implementation of new or revised versions. Staff must ensure that they are adequately trained in the new procedure and must make sure that all copies of superseded versions are promptly withdrawn from use unless notified otherwise by the SOP Controller.

The definitive versions of all R&D Unit SOPs appear online. If you are reading this in printed form check that the version number and date below is the most recent one as shown on the R&D Unit website: www.research.yorkhospitals.nhs.uk/sops-and-guidance-/ and/or Q-Pulse

SOP Reference:	Pharm/S92
Version Number:	3.0
Author:	Cheryl Donne
Implementation date of current version:	9 th October 2024

Approved by:	Name/Position:	Poppy Cottrell-Howe, Pharmacy Clinical Trials Manager
	Date:	19 th September 2024
	Name/Position:	Sarah Sheath, SOP Controller
	Date:	11 th September

This SOP will normally be reviewed every 3 years unless changes to the legislation require otherwise

Version History Log

This area should detail the version history for this document. It should detail the key elements of the changes to the versions.

Version	Date Implemented	Reviewers	Details of significant changes
1.0	14 th September 2015		
2.0	11 th August 2020		Change of author. Change of link to R&D website. Clarity of working processes to cover both York and Scarborough sites. All teams' responsibilities updated. Change of author. Updated flowcharts. Change of title.
3.0	9 th October 2024	Rachel Spooner	Change of Trust name and other updates in text of SOP relating to processes. CT will supply all supplementary items.

Contents

	<u>Page No</u>
1 Introduction, Background and Purpose	1
2 Who Should Use This SOP	1
3 When this SOP Should be Used	1
4 Procedure(s)	1
5 Related SOPs and Documents	6
6 Appendix 1) Processing research prescriptions at York	7
7 Appendix 1) Processing research prescriptions at Scarborough	8

UNCONTROLLED DOCUMENT WHEN PRINTED

1 Introduction, Background and Purpose

This Standard Operating Procedure (SOP) should be used to ensure that all Investigational Medicinal Products (IMPs) and Non Investigational Medicinal Products (NIMPs) involving chemotherapy are prescribed correctly, clinically checked by a specialist oncology/haematology pharmacist, ordered and dispensed in accordance with the protocol, and given / administered to the patient in a safe and timely manner.

2 Who Should Use This SOP

The procedures described should be followed by oncology/haematology clinical trial prescribers who have been authorised to prescribe on the trial specific delegation log, members of the oncology/haematology research team, trained and authorised oncology/haematology pharmacists, members of the satellite unit team and the pharmacy clinical trials team.

3 When this SOP Should be Used

This SOP should be used when prescribing and processing clinical trial prescriptions involving oncology and haematology medication.

4 Procedure(s)

Flow charts for the order of processing Chemotherapy prescriptions for York & Scarborough Hospital sites are shown in Appendix 1 and 2 of this SOP.

All chemotherapy prescriptions will be generated on Chemocare unless prior exceptional agreement has been made at trial set-up.

Not all trials will be able to run in the format outlined below.

Some trials will have specific ways in which they will need dispensing due to blinding restrictions or other contributing factors. This will be communicated with the relevant research team when the study opens.

Research team responsibilities:

Contact the pharmacy clinical trials team as soon as a patient is booked in for a visit to collect/receive medication as part of a clinical trial this will also include any potential new patients that might enter into the study as well as all patients continuing on study treatment to allow for supplies to be ordered.

Failure to inform the pharmacy clinical trials team of prescriptions may result in the dose being delayed or missed.

For patients collecting their medication from Scarborough consider booking the patient in for their visit after 2pm if possible. This will allow for prescriptions to be sent on same day routine hospital transport if for any reason the prescription is unable to be generated in advance.

Inform the pharmacy clinical trials team if there are any cancellations or changes to appointments or treatments.

The research team must contact the oncology satellite unit directly when Chemocare prescriptions have been generated if the prescriber has not already done so. The sooner the prescription can be generated by the prescriber it will allow for more time for the rest of the processes and will help to reduce errors. The oncology satellite unit will then clinically check the prescription before releasing it to the pharmacy clinical trials team to be dispensed. **Failure to inform the satellite team of prescriptions will result in the prescriptions not being released for dispensing which will delay patient supply.**

The information required by the oncology satellite unit to locate and process the chemocare prescription will be: patient details, date and time of clinic visit or treatment & how many courses of treatment are expected. Also inform the pharmacy clinical trials team so they can be ready to receive the prescription once checked.

At least 48 hours' notice is required for all products requiring preparation by the Aseptic unit. The research team must contact the oncology satellite unit and the pharmacy clinical trials team if a dose is required within less than 48 hours. This will be discussed with the aseptic unit, and doses cannot be guaranteed to be prepared in this case.

If a prescription is generated and printed in clinic (Usually Haematology prescriptions), the research nurse should ensure the pharmacy satellite unit are aware that the patient is waiting. The nurse can wait for the clinical check by an authorised Pharmacist and then bring it themselves to clinical trials pharmacy or make arrangements with the oncology satellite to get it to Pharmacy clinical trials for dispensing.

Collect the completed prescriptions from the pharmacy clinical trials at York or from the main pharmacy reception at Scarborough. For prescriptions with space to sign for collection, sign the section when collecting from pharmacy.

A copy of the prescription will be provided for the patients notes. The original prescription will be kept in the pharmacy site file.

For patients collecting from **Scarborough** copies of the prescription will be kept by the research teams. The prescription will also be accompanied with a Transporting IMP between the York and Scarborough sites form Pharm/F84 this will require signing on collection and must be kept. The completed forms will be collected by pharmacy clinical trials staff. If for any reason the prescription cannot be sent to the patient on routine transport liaise with the pharmacy clinical trials team to make arrangements to get the medication delivered to the patient. If the patient's prescription gets delivered to their house, obtain their signature on the Transporting IMP between the York and Scarborough sites form Pharm/F84.

Prescriber's responsibilities:

Only prescribers with the appropriate duties detailed on the individual trial delegation log are authorised to prescribe for a clinical trial. **This is for all stages of Chemocare prescribing.** It is the prescribing doctor's responsibility to be aware if they are able to prescribe. Prescriptions will be checked by an oncology satellite pharmacist and Pharmacy clinical trials and any changes required could delay the supply of medication to the patient.

Chemocare Prescriptions for oral IMPs and nIMPs can be either printed by the prescriber in clinic or by the oncology satellite unit. Aseptically prepared items must be printed in the oncology satellite unit. The prescriber should add the patient's trial ID number and allergy status to the prescription electronically.

If required for the trial the nurses must be contacted to perform any randomisation/allocation in the IWRS so that the correct IMP treatment pack number or treatment arm can be allocated by pharmacy.

The start date of treatment, cycle and visit number, and quantity of medication must be prescribed in line with the study protocol.

If a prescribing error/omission is detected by the oncology satellite unit, the prescriber will be required to amend it they will be contacted by the most suitable method as the prescriber maybe off site. Any changes to the prescription must be completed by a prescriber named on the delegation log for the study. Changes must be made electronically using the Chemocare system. This may result in delays to the patient receiving treatment.

Serious errors will be reported through the DATIX System.

At least 48 hours' notice is required for all products requiring preparation by the Aseptic unit, if urgent items are needed, contact all the relevant parties to make arrangements to supply and prepare the items.

For patients that collect prescriptions from Scarborough consider that the prescription is dispensed on the York site and prescriptions and medication will be sent on routine hospital transport that leaves the York site at 12pm daily and will arrive at the Scarborough site at approximately 1.30pm/2pm the same day. Allow enough time for the prescription to be checked, dispensed and sent on transport for the patient to collect in clinic. (Minimum 24 hours' notice) Failure to give enough notice will result in patient's not being able to collect their medication and will require alternative delivery methods.

Pharmacy clinical trials team responsibilities:

When informed by the research teams of a patient attending clinic to collect/receive a prescription, add the appointment to the workflow diary on Edge to allow for correct planning.

Ensure there are adequate supplies available for the patient's visits.

Clinical trials pharmacy will be responsible for managing stock of IMP for all studies. Effective communication of patient's treatment dates and appointments will enable the IMP stock to be available when required.

When randomisations/allocations are generated by the research teams, forward a copy to the oncology satellite team if needed for clinical checking.

Only prescribers that have prescribing delegated duties on the trial delegation log can prescribe for a clinical trial. The clinical trials pharmacy team will check the prescription against the delegation log once the prescription is received in the department. The most up to date copy of the delegation can be obtained from the research teams.

Pharmacy clinical trials team will notify the aseptic team to allow them to create worksheets to make the requested product.

Pharmacy clinical trials will dispense the required items on the prescription, listed in the study protocol that are IMP or nIMP that require accountability which include:

Oral items:

- IMP or nIMP supplied by the sponsor.
- Products classed by the sponsor as IMP and nIMP which is sourced, ordered, supplied, and accounted for by the pharmacy clinical trials team.

Supply of standard/supporting elements of the chemocare prescription (medication not classed as IMP or nIMP as part of the study) will also be supplied if required and stock levels are available to accommodate these fulfilled from the main pharmacy stock level.

Aseptically prepared items:

- IMP or nIMP supplied by the sponsor - the raw elements and sundry items used to prepare the product will be dispensed to the aseptic team directly before the product is to be prepared to maintain accountability and temperature monitoring.

Depending on the individual trial arrangements pharmacy clinical trials may need to supply trial specific labels for items being supplied by the oncology satellite unit or aseptics. Refer to the study specific SOPs in the pharmacy site file.

nIMP which are not supplied by the sponsor may require accountability to be completed by the pharmacy clinical trials. Complete the relevant accountability and patient specific logs retrospectively when the associated documentation is provided by the oncology satellite or aseptics. Refer to the study specific SOPs in the pharmacy site file for clarification if this is required.

The Pharmacy clinical trials team will perform accountability for IMP and nIMP for products made in the aseptic unit, photocopy/return processed worksheets and preform label accountability as required. Store the copied paperwork in the pharmacy site file with the patient's prescription and return the original to aseptics.

Pharmacy clinical trials may be required to deliver products directly to the treatment areas for some blinded studies; these arrangements will be made prior to the study opening.

The pharmacy clinical trials team will be responsible for liaising with the research teams to ensure the completed prescription is collected or transported ready for the patients visit.

For patient's collecting their prescription from the Scarborough site, follow the study specific SOPs for transporting IMP between sites in the pharmacy site file. Prescriptions will be sent with a Transporting IMP between the York and Scarborough sites form Pharm/F84. These completed forms will be collected regularly from the Scarborough research team and filed in the pharmacy site file upon return.

If the patient collects their prescription from pharmacy clinical trials/gets delivered to their house. Obtain their signature on either the prescription or Transporting IMP between the York and Scarborough sites form Pharm/F84. If a taxi is used follow the main pharmacy procedure. Store associated paperwork and correspondence with the patient's prescription in the pharmacy site file.

The oncology satellite unit responsibilities:

All clinical trials oncology and haematology prescriptions will be processed through the oncology satellite unit for a clinical check for both the York and Scarborough sites.

All prescriptions will be clinically checked in accordance with SOPSAT19 (Systemic anti-cancer therapy clinical check parameters)

The clinically checking pharmacist must be trained how to check clinical trial prescriptions.

All items supplied by the sponsor (IMP or nIMP) will be dispensed by the pharmacy clinical trials team; when stock allows other items on the prescription may also be dispensed by the Pharmacy Clinical Trials team Standard of Care IV products (Items that are not IMP or nIMP that are not supplied by the sponsor/pharmacy clinical trials) requiring aseptic preparation will be ordered by the oncology satellite team directly to the aseptics.

Ready to administer (RTA) products not supplied by the sponsor will be supplied by aseptics as normal practice.

A copy of the most up to date delegation log can be obtained from the pharmacy clinical trials team or the research team if required for checking or query purposes. The oncology satellite checking pharmacist will contact the pharmacy trials team to forward the patients randomisation when required.

The checking pharmacist can add the patient's trial number and allergy status to the prescription if the prescriber has not done so by using a suitable trial document or source such as the patient's randomisation paperwork. This can be done electronically or manually.

The oncology satellite unit will call pharmacy clinical trials when a checked prescription is ready for collection or hand it to the research nurse to take to pharmacy clinical trials.

Requests for additional/supportive medication should be annotated on the prescriptions and can be dispensed by the clinical trials team if stock allows. If there are issues with this the pharmacy clinical trials team who will arrange supply via Lloyds.

The oncology satellite unit will contact the prescriber directly to correct any prescribing issues regarding the prescriptions and feedback to the research nurses and pharmacy clinical trials team of possible delays.

The pharmacist providing the clinical check must sign the prescription either electronically or manually indicating the Clinical check is complete so dispensing can be done. This pharmacist should also have signed the oncology satellite signature log held in Pharmacy Clinical Trials.

For all products supplied as part of a clinical trial that requires accountability by the sponsor order/dispensing paperwork and worksheets should be supplied to the pharmacy clinical trials team for photocopying and saving in the pharmacy site file.

5 Related SOPs and Documents

York Teaching Hospital NHS Foundation Trust Medicines Code

MHRA Grey Guide

EU-GMP Annex 13: Investigational Medicinal Products


International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines

SOPSAT19 Systemic Anti-Cancer Therapy Clinical Check Parameters

Pharm/F84 – Transporting IMP between York and Scarborough Sites Form

UNCONTROLLED DOCUMENT WHEN PRINTED

Appendix 1) **Processing research prescriptions at York**



Please note that not all trials will be able to run in the format outlined above. Some trials will have specific ways in which they will need dispensing due to blinding restrictions. This will be communicated with the relevant research team when the study opens.

Phone numbers
 Pharmacy Clinical Trials office – 72 1684
 Oncology Satellite office - 72 1298
 Pharmacy Aseptics – 72 5977

Appendix 2) Processing research prescriptions at Scarborough

